Navigation Links
Savient Announces the Election of Robert G. Savage to its Board of Directors
Date:12/5/2012

BRIDGEWATER, N.J., Dec. 5, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that Robert (Bob) G. Savage has been elected to the Company's Board of Directors, effective December 5, 2012.

"Bob is a proven leader with an exceptional track record of success, and we are fortunate to have a pharmaceutical executive with such a wealth of experience join our Board of Directors," stated Stephen O. Jaeger, Chairman of Savient's Board of Directors.

Mr. Savage is currently President and CEO of Strategic Imagery LLC, a consulting company of which he is the principal.  Previously, Mr. Savage was Group Vice President and President of the Worldwide General Therapeutics & Inflammation Business of Pharmacia Corporation from 2002 until its acquisition by Pfizer, Inc. in 2003.  Prior to that role, he held several senior positions with Johnson & Johnson, including Worldwide Chairman of the Pharmaceuticals Group, Company Group Chairman for the North American pharmaceuticals business, President of Ortho-McNeil Pharmaceuticals and Vice President of Sales and Marketing. Earlier in his career, he served in a variety of senior marketing, operations, business development and strategic planning positions for Hoffmann-La Roche, Inc.  Mr. Savage currently serves as a director of EpiCept Corporation, Nuovo Biologics and The Medicines Company.  Mr. Savage received a B.S. in Biology from Upsala College and an M.B.A. from Rutgers University.

"Given Bob's extensive experience in domestic and international marketing, business development and operations, we are confident that he will immediately prove to be an invaluable addition to the board and as an advisor to our senior management team especially in light of the anticipated approval and launch of KRYSTEXXA® in the EU," said Lou Ferrari, President and Chief Executive Officer of Savient.  "His strategic vision and expertise in orchestrating major product launches with renowned success will be instrumental to Savient's ongoing commitment to providing KRYSTEXXA as a treatment option to patients suffering from refractory chronic gout (RCG) in the U.S. and around the world." 

ABOUT SAVIENT PHARMACEUTICALS, INC.
Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP").  Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA.  Savient also supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S. For more information, please visit the Company's website at www.savient.com

SVNT - GContact:Savient Pharmaceuticals, Inc.

Burns McClellan John P. Hamill

Caitlyn MurphySenior Vice President and Chief Financial Officercmurphy@burnsmc.com information@savient.com

(212) 213-0006(732) 418-9300
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals Reports Third Quarter 2012 Financial Results
2. Savient Pharmaceuticals to Present at the 6th Annual Imperial Capital Global Opportunities Conference
3. Savient Pharmaceuticals to Present at the Rodman & Renshaw 14th Annual Healthcare Conference
4. Savient Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Growth Conference
5. Savient Pharmaceuticals Adopts Stockholder Rights Plan
6. Savient Pharmaceuticals Receives Favorable Decision In Tang Capital Litigation
7. Savient Pharmaceuticals to Hold Second Quarter 2012 Financial Results Conference Call on Wednesday, August 8, 2012
8. Savient Pharmaceuticals Announces CEO Appointment and Reorganization Plan to Drive Long-Term Growth
9. Savient Pharmaceuticals to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
10. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
11. Harrington Discovery Institute at University Hospitals Case Medical Center Announces Grant Funding to Physician-Scientists at Major Academic Medical Centers to Support New Drug Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2017)... YORK , Sept. 12, 2017   EcoVadis , the leading ... has published the first annual edition of its Global CSR Risk and ... companies evaluated by EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 ... ... Index ...
(Date:9/9/2017)... 2017 Dealmed Medical Supplies, New ... equipment, supplies, drugs, vaccines, and specialty medical products and ... agreement to acquire Vantage Medical Supplies, a major distributor ... Holtsville, New York . ... emerging medical practices, will operate under the Dealmed name ...
(Date:9/7/2017)... , Sept. 7, 2017 Caris Life ... on fulfilling the promise of precision medicine, today ... the benefits of its molecular profiling approach in ... comprehensive genomic profiling plus (CGP+) with Caris Molecular ... tumor on a molecular level, leading to more ...
Breaking Medicine Technology:
(Date:9/21/2017)... ... 21, 2017 , ... Hair restoration surgery is having a ... the International Society of Hair Restoration Surgery (ISHRS). The worldwide volume ... with 635,189 procedures performed in 2016. , "Like other forms of cosmetic ...
(Date:9/21/2017)... ... September 21, 2017 , ... Bill Howe Plumbing’s mission is to create an ... to the community. For over 37 years, they have operated with their mission at ... in San Diego. They were chosen as the Best San Diego plumber in ...
(Date:9/21/2017)... , ... September 21, 2017 , ... ... Microscan’s LVS 7510 at the Global GS1 Healthcare Conference 2017 in Chicago, IL ... life-sciences industry for ensuring label quality and improving patient safety. , ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... highly accurate cancer screening tests, has received two prestigious recognitions that acknowledge the ... rates. , Preora has been named a Top 100 Finalist for ...
(Date:9/21/2017)... ... 2017 , ... A new addiction treatment service has opened ... Virginia faces an opioid epidemic. , Last year, Virginia saw at ... from 2015, underscoring the need for additional addiction treatment options. , Calyx Recovery ...
Breaking Medicine News(10 mins):